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Abstract
Objective—To examine the potential effects of prenatal smokeless tobacco use on selected birth 
outcomes. Design. A population-based, case–control study using a retrospective medical record 
review.
Population—Singleton deliveries 1997–2005 to Alaska Native women residing in western 
Alaska.
Methods—Hospital discharge codes were used to identify potential case deliveries and a random 
control sample. Data on tobacco use and confirmation of pregnancy outcomes were abstracted 
from medical records for 1123 deliveries. Logistic regression was used to examine associations 
between tobacco use and pregnancy outcomes. Adjusted odds ratios (OR), 95% confidence 
intervals (95% CI), and p-values were calculated.
Main outcomes measures—Preterm delivery, pregnancy-associated hypertension, and 
placental abruption.
Results—In unadjusted analysis, smokeless tobacco use was not significantly associated with 
pre-term delivery (OR 1.44, 95% CI 0.97–2.15). After adjustment for parity, pre-pregnancy body 
mass index, and maternal age, the point estimate was attenuated and remained non-significant. No 
significant associations were observed between smokeless tobacco use and pregnancy-associated 
hypertension (adjusted OR 0.92, 95% CI 0.56–1.51) or placental abruption (adjusted OR 1.11, 
95% CI 0.53–2.33).
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Conclusions—Prenatal smokeless tobacco use does not appear to reduce risk of pregnancy-
associated hypertension or to substantially increase risk of abruption. An association between 
smokeless tobacco and pre-term delivery could not be ruled out. Components in tobacco other than 
nicotine likely play a major role in decreased pre-eclampsia risk in smokers. Nicotine adversely 
affects fetal neurodevelopment and our results should not be construed to mean that smokeless 
tobacco use is safe during pregnancy.
Keywords
Abruption; cigarettes; pregnancy; pregnancy-associated hypertension; preterm delivery; smokeless 
tobacco
Introduction
Cigarette smoking during pregnancy increases the risk of many adverse pregnancy 
outcomes, including fetal growth restriction, preterm delivery, placenta previa and placental 
abruption; however, smoking reduces the risk of pre-eclampsia (1,2). The underlying 
mechanisms are not established, but because smokeless tobacco products do not expose 
users to products of combustion, it has been suggested that smokeless tobacco is safer than 
cigarettes (3,4). However, data suggest that maternal smokeless tobacco use may adversely 
affect pregnancy outcomes (5–7). Because smokeless tobacco is gaining popularity among 
women in many parts of the world (8), it is important to establish the health effects of 
prenatal use. In addition, comparing pregnancy outcomes in smokers and smokeless tobacco 
users may provide insight into the mechanisms underlying the adverse effects of smoking on 
maternal and infant health.
In parts of western Alaska, the prevalence of smokeless tobacco use in pregnant Alaska 
Native women exceeds 50% (9). Both commercial and homemade products are used; the 
homemade mixture (iqmik) includes leaf tobacco and ash from burned punk fungus, willow 
bush or driftwood. Because adding ash raises the pH and the amount of free (unprotonated) 
nicotine, nicotine exposure in users of iqmik is believed to be high (10). In response to 
concerns from local medical providers about the potential health effects of iqmik and 
commercial chew tobacco use during pregnancy, we conducted a population-based, 
retrospective case–control study to examine associations between maternal smokeless 
tobacco use in Alaska Native women and adverse birth outcomes. Based on input from local 
providers, a review of published literature, and a feasibility assessment, we selected for 
study preterm delivery, pregnancy-associated hypertension and placental abruption. To 
determine whether expected associations between cigarette smoking and adverse pregnancy 
outcomes were observed in this population, analyses of maternal cigarette smoking and 
these outcomes were also performed.
Material and methods
A large population of indigenous people resides in the study region in western Alaska and is 
relatively homogeneous with respect to socioeconomic status and culture. Nearly all (96%) 
pregnant Alaska Native women in the study region receive their prenatal care through a 
single health system, which includes village-based clinics staffed by health aides and a 
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regional hospital/medical center; women with high-risk pregnancies are referred to the 
Alaska Native Medical Center in Anchorage or to Providence Alaska Medical Center in 
Anchorage for specialty care during pregnancy and/or for delivery. Home and village 
deliveries are rare.
We used the electronic Resource and Patient Management Systems of the regional hospital/
medical center and the Alaska Native Medical Center, to identify singleton deliveries to 
Alaska Native women who resided in the study region during pregnancy, used healthcare 
services at the regional hospital/medical center, and delivered at the regional hospital or a 
referral hospital (Alaska Native Medical Center or Providence Alaska Medical Center) 
between 1 January 1997 and 31 December 2005. The electronic data systems were searched 
for hospitalizations with International Classification of Diseases, 9th Revision, Clinical 
Modification (ICD9-CM) discharge codes indicating delivery of an infant (live born or 
stillborn). Procedure codes for manually assisted delivery or cesarean section were also 
identified (see Supplementary material, Appendix S1). Eligible deliveries at Providence 
Alaska Medical Center were identified from transfer records.
From the created data set of singleton deliveries, we identified potential case deliveries using 
ICD9-CM codes for the outcomes of interest (see Supplementary material, Appendix S1). 
Because we planned to examine multiple outcomes, we created one main control pool 
consisting of a random sample of approximately 10% of all singleton deliveries. Deliveries 
for the main control pool were selected without regard for case status. For each individual 
case–control analysis, the control deliveries consisted of those deliveries in the control pool 
that did not have the outcome of interest and that met the additional inclusion criteria for that 
particular analysis.
Two trained nurses completed the medical record abstractions. Inclusion criteria were: 
delivery ≥22 weeks of gestation; no maternal alcohol use after the first trimester and no 
cocaine, amphetamine, or opioid use at any time during pregnancy; and the infant was born 
without a major congenital anomaly. From records meeting inclusion criteria, abstractors 
collected: tobacco exposure; infant gender and birth size; maternal age at delivery, marital 
status, and highest level of education; gravidity and parity; maternal height and pre-
pregnancy weight; maternal pre-existing medical conditions (including diabetes and chronic 
hypertension); provider’s diagnosis of pregnancy complications; maternal blood pressure 
and urine protein measurements with corresponding gestational age estimates; maternal 
antihypertensive medication use before, during and after pregnancy; medications used 
during labor and delivery; gestational age at delivery (based on last menstrual period, 
ultrasound and provider’s best estimate); and live birth or stillbirth. Maternal medical 
records before pregnancy and after delivery were also reviewed for evidence of pre-existing 
or persistent hypertension.
To ensure data quality and accuracy, three Centers for Disease Control investigators re-
abstracted key variables from approximately 10% of the records to validate outcomes and 
tobacco exposure. Discrepancies were reviewed with the abstractors and retraining was 
provided to maintain consistency in abstraction practices.
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All records meeting inclusion criteria were reviewed in detail to establish case status. Each 
delivery was eligible to become a case for any of the outcomes, regardless of ICD9-CM 
code, and regardless of whether the delivery was included in the main control pool. A 
delivery could serve as a case for more than one outcome and a delivery from the main 
control pool could be included in more than one control group.
Preterm case deliveries were <37 completed weeks gestation and control deliveries were ≥37 
completed weeks gestation (based on the provider’s best estimate of gestational age). We 
excluded stillborn deliveries, deliveries in which gestational age was unknown, case 
deliveries with a birthweight not plausible for a preterm birth (>95th centile for a 36-week 
delivery or 3980 g) and control deliveries with a birthweight not plausible for a term birth 
(<5th percentile for a 37-week delivery or 2390 g). Percentiles were determined using US 
vital statistics data for live births to American Indian and Alaska Native women.
Pregnancy-associated hypertension (PAH) case deliveries were deliveries with any clinician-
diagnosed hypertensive disorder of pregnancy [pre-eclampsia, gestational hypertension, 
eclampsia, or HELLP syndrome (hemolysis, elevated liver enzymes, low platelet count)] and 
documentation of hypertension (systolic blood pressure ≥140 mmHg or diastolic blood 
pressure ≥90 mmHg) on two or more occasions during pregnancy and separated by at least 4 
h. We required that case deliveries with hypertension only during labor had a diastoloc blood 
pressure ≥90 mmHg, as well as proteinuria or treatment with magnesium sulfate. Deliveries 
with evidence of pre-existing hypertension or renal disease were excluded from both case 
and control groups. Case deliveries were subdivided into pre-eclampsia (hypertension with 
proteinuria, defined as a urine protein concentration of ≥300 mg/ 24 h, if a 24-h test was 
available, ≥1000 mg/L, if concentration was available, or ≥2+ on a urine dip) and gestational 
hypertension without proteinuria. Control deliveries had no hypertensive disorder diagnosis, 
no documented hypertension or proteinuria during pregnancy, no evidence of pre-existing 
hypertension or renal disease. We excluded from both case and control groups deliveries 
with missing antenatal or delivery hospitalization records or in which the mother received no 
prenatal care.
Abruption was defined as clinician-diagnosed placental abruption. In a sub-analysis, all 
deliveries with evidence of abruption from clinician diagnosis, placental pathology report, or 
report of abruption or blood in the amniotic fluid in the labor and delivery record, were 
included in the case group. The control group for both the main analysis and sub-analysis 
consisted of deliveries to women with no evidence of abruption from any source.
Tobacco exposure was abstracted from prenatal medical records, which included standard 
prenatal substance abuse forms. The type of product (cigarettes, iqmik or commercial chew 
tobacco) and the frequency of use were abstracted for two trimester groupings: the first/
second trimester and the third trimester. The highest frequency of tobacco use recorded for 
each trimester grouping was abstracted for each type of tobacco.
Statistical analysis
Before initiating the study, we conducted a feasibility assessment and performed power 
calculations to determine whether the available sample size (all singleton deliveries over a 9-
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year period) was sufficient to detect associations between smokeless tobacco exposure and 
the outcomes of interest. We estimated that the sample would provide sufficient power 
(≥80%) to detect a two-fold increase in preterm delivery in smokeless tobacco users, a two-
fold increase in PAH, and a three-fold increase in abruption compared with tobacco non-
users. These estimates were determined to be acceptable based on our review of published 
studies available at the time. There were no previous studies on risk of abruption associated 
with smokeless tobacco use; however, local providers felt that the risk of abruption was 
greatly increased in smokeless tobacco users.
We categorized pregnancies into mutually exclusive exposure groups: no maternal tobacco 
use, continuous use of smokeless tobacco throughout pregnancy, use of smokeless tobacco 
but the mother quit during pregnancy, continuous maternal cigarette smoking, cigarette 
smoking but the mother quit during pregnancy, and use of both products (dual use). Because 
we had limited information on the use of cigarettes and smokeless products among dual 
users (concurrent dual use vs. switching from one product type to another), we excluded 
these pregnancies from all risk analyses. We also excluded from risk analyses pregnancies in 
which mothers quit tobacco because previous research suggests that cessation during 
pregnancy attenuates the effects of tobacco on some pregnancy outcomes, and because the 
number of quitters was too small to study separately.
Logistic regression was used to generate crude and adjusted odds ratios and 95% confidence 
intervals for deliveries to women with continuous chewing and with continuous smoking. 
Adjustment factors initially included in all analyses were maternal age, marital status, 
height, pre-pregnancy body mass index and parity. Education was not included in models 
because of the high proportion of missing values. Parameter estimates could not be 
computed for some models that included marital status because one of the categories of 
marital status contained only case or only control deliveries, so marital status was dropped 
from all models. Finally, maternal height contributed little to models and was also dropped. 
Final models for all outcomes therefore included maternal age, pre-pregnancy body mass 
index and parity. To determine whether missing information introduced bias in the full 
models, crude models were rerun using only data from deliveries included in the full models. 
Analyses were performed using generalized estimating equations to correct for correlation 
within women because mothers could be selected more than once during the study period if 
they had more than one singleton pregnancy.
Statistical analyses were performed using SAS software V.9 (SAS Institute Inc., Cary, NC, 
USA) for Windows. The study proposal and related materials were reviewed and approved 
by the institutional review boards (IRBs) of the Centers for Disease Control and Prevention 
and the Mayo Clinic, and by the Alaska Area IRB. The Alaska Area IRB approved the 
protocol by full committee, expedited review.
Results
A total of 1296 deliveries were selected for inclusion in this study, including 844 deliveries 
selected based on ICD9-CM codes for preterm delivery, PAH and/or placental abruption, and 
557 randomly selected deliveries. Of the 557 deliveries, 105 (18.9%) also had been selected 
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as potential case deliveries based on ICD9-CM codes. We excluded from the full analysis 
164 deliveries because of substance abuse or congenital anomalies and nine because tobacco 
exposure was unknown, leaving 1123 for final analysis. Of these, 707 were potential case 
deliveries and 502 made up the main control pool. Deliveries in the control pool were 
eligible to become case deliveries for any of the outcomes. Case and control designations are 
depicted in Figure 1.
For analysis of preterm delivery, 1104 deliveries were eligible for inclusion; 291 were 
preterm deliveries (3.4% of which were identified from medical record reviews in the 
control pool and not from ICD9-CM codes) and 449 were term control deliveries (Figure 1). 
Preterm case and control deliveries differed with respect to maternal age and cases were 
more likely than controls to be complicated by PAH or by abruption (Table 1). In unadjusted 
analysis, continuous maternal smokeless tobacco use was not significantly associated with 
preterm delivery (odds ratio = 1.44, 95% confidence interval 0.97–2.15) (Table 2). After 
adjustment for potential confounders, the point estimate was slightly attenuated and 
remained non-significant.
In unadjusted and adjusted analyses, there was no significant association observed between 
continuous maternal smoking and preterm delivery, although the point estimates were >1, as 
expected.
For analysis of PAH, 1090 deliveries were eligible for inclusion; 224 deliveries were PAH 
cases (3.1% of which were identified from medical record reviews in the main control pool 
and not from ICD9-CM codes) and 315 were control deliveries not complicated by 
hypertension (Figure 1). The PAH case and control deliveries differed with respect to 
maternal age, marital status and parity (data not shown). Of the case deliveries, 17% were 
also complicated by preterm delivery (compared with 5.1% of controls, p < 0.001), and 
3.6% were also complicated by abruption (compared with 1.3% of controls, p = 0.07). In 
unadjusted analysis, there was no significant association observed between continuous 
maternal smokeless tobacco use and PAH (Table 3). Adjustment for potential confounders 
did not change this finding. When pre-eclampsia and gestational hypertension were 
examined separately, there was no significant association between these outcomes and 
maternal smokeless tobacco use.
In unadjusted and adjusted analyses, there were no sig-nificant associations observed 
between maternal cigarette smoking and PAH, although point estimates were <1, as 
expected. This finding did not change when pre-eclampsia and gestational hypertension 
were examined separately (Table 3).
There were 82 abruption case deliveries (all identified from ICD9-CM codes) and 485 
control deliveries. Abruption case and control deliveries differed with respect to maternal 
age (data not shown). Thirty-nine percent of case deliveries were also preterm (compared 
with 7% of controls, p < 0.001), and 9.8% were also complicated by PAH (compared with 
7% of controls p = 0.38). In unadjusted and adjusted analyses, there were no significant 
associations between maternal smokeless tobacco use and placental abruption (Table 4). An 
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expanded definition of abruption did not change this finding. There were no sig-nificant 
associations between maternal cigarette smoking and abruption (Table 4).
Discussion
The adverse effects of prenatal cigarette smoking are well documented, but the underlying 
mechanisms and components involved are not fully understood (11). In contrast, smokeless 
tobacco use is prevalent or gaining in popularity among women in many parts of the world, 
but little is known about the potential health effects of use during pregnancy. While cigarette 
smoking and smokeless tobacco use result in maternal and fetal exposure to nicotine, 
smokeless tobacco use does not result in exposure to products of combustion. Comparing 
pregnancy outcomes in smokers and smokeless tobacco users will increase our 
understanding of the components and mechanisms involved and provide important clinical 
information for populations in which smokeless tobacco use in women is high.
In our study, we found no statistically significant associations between smokeless tobacco 
use and increased risk of preterm delivery, PAH or placental abruption, although the point 
estimate for smokeless tobacco and preterm delivery was similar to those previously 
reported (11,12). Similar to previous studies (7), we did not find evidence that smokeless 
tobacco use protects against pre-eclampsia.
Cigarette smoking during pregnancy is associated with a modest increase in the risk of 
preterm delivery, with an estimated relative risk of 1.27 (12). Researchers also found an 
increased risk for preterm delivery in smokeless tobacco users. In a recent analysis using 
data from the Swedish Birth Register, the authors found a 1.3-fold increase in preterm 
delivery among smokeless tobacco (snus) users (13), and in a study in India, smokeless 
tobacco use was associated with a two-fold increase in preterm delivery (5). However, in a 
study in South Africa, the authors found no increase in deliveries <36 weeks of gestation 
among smokeless tobacco users (14). In our study, the adjusted odds ratio for preterm 
delivery overall was 1.23, similar to that in the Swedish study, although ours was not 
statistically significant. Because our sample size was insufficient to detect a modest 
association, it remains possible that smokeless tobacco increases the risk of preterm delivery 
and that nicotine contributes to the increased risk of preterm delivery in both smokeless 
tobacco users and smokers.
A reduced pre-eclampsia risk of approximately 30% among women who smoke during 
pregnancy has been well documented (11). It has been hypothesized that pre-eclampsia is 
the result of an imbalance of maternal pro-angiogenic and anti-angiogenic factors, with a 
shift toward an anti-angiogenic state. Further, carbon monoxide may play a key role in the 
protective effects of tobacco against pre-eclampsia through modulatory effects on the pro-
angiogenic and anti-angiogenic balance, toward a pro-angiogenic state (15). Consistent with 
this latter hypothesis, the authors of a recent analysis using Swedish Birth Register data 
found no significant association between smokeless tobacco use and pre-eclampsia (adjusted 
odds ratio 1.11, 95% confidence interval 0.97–1.28) (16), which would be expected if 
products of combustion other than nicotine were responsible for the protective effects of 
smoking. In the current study, which has the advantage of a detailed medical record review, 
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our findings for both PAH and pre-eclampsia were similar to the Swedish study in that we 
did not find a protective effect. Together, these findings support that tobacco components 
other than nicotine play a major role in reducing the risk of PAH and pre-eclampsia in 
cigarette smokers.
Smoking during pregnancy is associated with an approximately two-fold increased risk for 
placental abruption (11). There are no previous publications to our knowledge in which 
abruption risk in smokeless tobacco users is assessed, and in the current study, we found no 
evidence that maternal smokeless tobacco use increases risk of abruption. Our findings 
should reassure local providers in Alaska that smokeless tobacco use does not appear to 
increase risk of abruption in their community.
Our study’s strengths include that it addresses concerns among local providers about 
important maternal health issues, our sample was population-based, and we were able to 
conduct thorough medical records reviews. In particular, we used rigorous case definitions 
for PAH, which is often difficult in larger population-based studies. In addition, because our 
study population is relatively homogeneous and smokeless tobacco use is ubiquitous, 
confounding is less of a concern compared with many other populations. Although 
smokeless tobacco products in Alaska are varied, especially with respect to the addition of 
ash, they are more similar than products used in India, strengthening our ability to draw 
conclusions related to effects of nicotine vs. products of combustion. Finally, although our 
sample was small, we were able to analyze women who smoked cigarettes, and our point 
estimates are consistent with previous literature for pre-term delivery and for PAH. This 
suggests that our tobacco exposure data were reasonably accurate.
This study has several limitations. There is variation in the types and composition of 
smokeless tobacco products used in this population, and it is possible that the use of some 
products could result in adverse health effects that we missed because effects were masked 
when smokeless products were combined in our analysis. We did not have information on 
the proportions of ash and tobacco used to make iqmik or the portion size chewed, nor did 
we have biochemical measures of tobacco exposure. Our sample was too small to detect 
modest associations; however, we based our sample size calculations on the best-available 
published and anecdotal data available at the time. Finally, we relied on retrospective 
assessments of exposure and outcomes, which may have resulted in misclassification.
Nicotine has known adverse effects on neurodevelopment and has been classified as a 
developmental toxin by the California Environmental Protection Agency (17). In our study, 
we were unable to assess potential negative effects of nicotine from maternal smokeless 
tobacco use on fetal neurodevelopment; this area remains a concern for our study 
population. In addition, we examined a limited number of outcomes; prospective studies are 
needed to identify and quantify other potential adverse effects of smokeless tobacco on 
reproductive and child health outcomes. Providers should continue to advise pregnant 
women to avoid all forms of tobacco.
ENGLAND et al. Page 8
Acta Obstet Gynecol Scand. Author manuscript; available in PMC 2018 April 03.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Conclusions
Maternal smokeless tobacco use during pregnancy does not appear to reduce risk of PAH or 
to substantially increase risk of abruption. An association between smokeless tobacco and 
preterm delivery could not be ruled out, leaving open the possibility that nicotine may play a 
central role in increasing risk of preterm delivery. Components in tobacco other than 
nicotine, such as products of combustion, may play a major role in decreased pre-eclampsia 
risk in smokers.
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Key Message
Prenatal smokeless tobacco use does not appear to reduce risk of pregnancy associated 
hypertension or to substantially increase risk of abruption in this population of Alaska 
Native women.
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Figure 1. 
Designation of case and control deliveries, Alaska Native women 1997–2005. 1Numbers do 
not add up to 1123 because the random sample was selected without regard for ICD9-CM 
codes. 2Case for at least one outcome (PTD, PAH, ABR). 372 served as both cases and 
control deliveries in different analyses. ABR, placental abruption; PAH, pregnancy-
associated hypertension; PTD, preterm delivery.
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Table 1
Preterm delivery: maternal characteristics of case and control deliveries, deliveries to quitters included, Alaska 
Native women 1997–2005.
Case deliveries (n = 291) Control deliveries (n = 449) p-value
Mother’s age, n (%) 0.03
 <20 years 49 (16.8) 58 (12.9)
 20–29 years 151 (51.9) 277 (61.7)
 30+ years 91 (31.3) 114 (25.4)
 Missing (n = 0)
Marital status, n (%) 0.37
 Married 122 (44.5) 204 (48.0)
 Single, Divorced, Widowed 152 (55.5) 221 (52.0)
 Missing (n = 41)
Education, n (%) 0.58
 Less than High School 74 (31.0) 97 (27.0)
 High School or General 138 (57.7) 218 (60.7)
 Educational Development
 Some college or higher 27 (11.3) 44 (12.3)
 Missing (n = 142)
Parity, n (%) 0.57
 Nulliparous 69 (23.7) 98 (21.9)
 Parous 222 (76.3) 349 (78.1)
 Missing (n = 2)
Trimester in prenatal care, n (%) 0.37
 First 148 (52.7) 250 (56.1)
 Second or third 133 (47.3) 196 (43.9)
 Missing (n = 13)
Body mass index, n (%) 0.13
 Lean/normal 118 (47.8) 169 (44.6)
 Overweight 78 (31.6) 108 (28.5)
 Obese 36 (14.6) 58 (15.3)
 Extremely obese 15 (6.1) 44 (11.6)
 Missing (n = 114)
Mother’s height, cm: mean (SD) 164.8 (26.6) 166.9 (28.4) 0.32
(Missing: n = 1)
Pregnancy-associated hypertension, n (%) 39 (13.4) 31 (6.9) <0.001
Placental abruption, n (%) 32 (11.0) 5 (1.1) <0.001
Tobacco use, n (%) 0.20
 Non-users 57 (19.6) 116 (25.8)
 Smoke cigarettes only, continued 40 (13.7) 48 (10.7)
 Smoke cigarettes only, quit 11 (3.8) 25 (5.6)
 Chew smokeless only, continued 149 (51.2) 210 (46.8)
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Case deliveries (n = 291) Control deliveries (n = 449) p-value
 Chew smokeless only, quit 10 (3.4) 10 (2.2)
 Smoke cigarettes and chew smokeless 24 (8.2) 40 (8.9)
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